butyrophilin subfamily 2 member A3, pseudogeneGenealiases: []
Q-omics provides the consensus-scored BTN2A3P profile across patient tissues and cancer cell-line models. BTN2A3P expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BTN2A3P is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, BTN2A3P RNA expression shows 20,232 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, HNSC, and KIRP as cancer lineages where BTN2A3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTN2A3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTN2A3P survival associations across molecular data types. BTN2A3P RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTN2A3P RNA expression–survival associations across cancer types. High BTN2A3P expression shows unfavorable associations in ACC, LGG, HNSC and ESCA, but favorable associations in READ and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BTN2A3P RNA expression.
This table summarizes BTN2A3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BTN2A3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTN2A3P shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, COAD, LIHC and KIRP. The HNSC box plot shows higher BTN2A3P RNA expression in tumor versus normal tissue (log2 FC = +1.026, t-test p < 0.001).
This table shows molecular features associated with BTN2A3P in patient tissues and cancer cell lines. In patient samples, BTN2A3P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, BTN2A3P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and NCI60_ALL.
